F.D.A. granted Gilead Sciences “orphan” drug status for its antiviral drug, remdesivir. The designation allows the pharmaceutical company to profit exclusively for seven years from the product, which is one of dozens being tested as a possible treatment for Covid-19.

Welcome • User Guide
ToS • Privacy • Canary
Donate • Bugs • License

©2025 Poal.co

1.1K

•

F.D.A. granted Gilead Sciences “orphan” drug status for its antiviral drug, remdesivir. The designation allows the pharmaceutical company to profit exclusively for seven years from the product, which is one of dozens being tested as a possible treatment for Covid-19. (theintercept.com)

(post is archived)

You are currently inside a comment thread.

Click here to see all the comments (1).

[–] [deleted] • 2 pts

Gilead Sciences’ remdesivir was developed with at least $79 million in U.S. tax payers money. In other words it should be free as the taxpayers have already paid for it......

link